1. Triple-negative breast cancer (TNBC) should be regarded as a working category that, although useful for current clinical decisions, may have only limited value as a defined biological category for future targeted therapy approaches due to its "triple negative" definition.
2. TNBCs are a highly heterogeneous group of tumors. Different approaches to classify these tumors have been established including classical pathology, mRNA expression profiling, DNA sequencing including analysis of copy number variations and structural rearrangements, and other molecular methods.
3. Important parameters of TNBC biology, include a high proliferative activity, an increased immune cell infiltrate, a basal-like and a mesenchymal phenotype, a deficiency in homologous recombination partly linked to a loss of BRCA1 function, and an expression of androgen receptors. 4 . The different molecular phenotypes are observed in overlapping small subsets of TNBC, and there are non-TNBC tumors that may present with identical molecular characteristics.
The current biological classifications do not allow a unified model of TNBC that can be
introduced as a molecular diagnostic tool.
6. Nevertheless, the increased knowledge on the molecular alterations in TNBC has led to several promising clinical approaches (including DNA damage response targeting, antiandrogens and immune checkpoint inhibitors) that are currently evaluated in phase [2] [3] clinical studies and might lead to new treatment strategies.
Search strategy and selection criteria:
We searched the medline database for the search terms "(therapy) AND (((("triple negative Considering the fact that a large number of clinical trials in TNBC are currently ongoing, we focussed this clinical series on those trials with published results for most clinical strategies.
Only for the new immune checkpoint inhibitor approaches, we have decided to include a table summarizing selected ongoing clinical trials. For other treatment strategies, we refer to published recent review articles that already provide an overview on ongoing clinical trials.
It should be noted that some of the most recent trial results have been reported only as meeting abstracts and presentations, and a more comprehensive description of the results is expected upon publication of the full-papers in the upcoming months. Due to the large number of clinical trials for the different TNBC subtypes it was not possible to include all clinical trials in this review article, and the presentations was focussed on those trials that were most intensely discussed in the medical community, based on the judgement of the authors. For additional trials, review articles are cited to provide readers with more details and more references than this Seminar has room for.
TNBC as a clinical problem
Triple-negative breast cancer (TNBC) represents 15% of breast carcinomas and is defined by the absence of the three main breast cancer biomarkers, i.e. lack of expression of estrogen receptor (ER) and progesterone receptor (PR) as well as lack of amplification/overexpression of HER2. 1 This negative definition together with biological and clinical heterogeneity has led authors to consider TNBC as "title of convenience" rather than a defined biological entity. 2 From a clinical perspective TNBC represents a highly relevant subgroup given that patients with TNBC do not benefit from endocrine or HER2-targeted agents and chemotherapy represents the only established therapeutic option. clinical decisions because the current evidence is based mainly on small phase 1 or 2 trials or biomarker-driven analyses of subcohorts.
Established chemotherapy strategies for TNBC
Despite their unfavorable prognosis when regarded as a single group, many TNBCs are highly chemotherapy sensitive, and TNBCs have an increased neoadjuvant response rate compared to other breast cancer subtypes. 6, 7, 8 This phenomenon (i.e. an improved chance of pathological complete response (pCR) in contrast to an overall unfavorable prognosis) is commonly referred to as "triple negative paradox." 9 It can be partly explained by the fact that highly-proliferating tumors have a poor prognosis and a high chance of response to chemotherapy at the same time. In addition, the poor prognosis of the group is driven by the very rapid onset of metastasis and poor prognosis of the TNBC subset that fail to respond to chemotherapy.
Relevant chemotherapy trials and metaanalyses are summarized in table 1. The ETCBCG overview has shown that the relative chemotherapy benefit resulting in approximately onethird reduction of breast cancer mortality is similar across breast cancer subtypes and independent of ER status. 10 In neoadjuvant studies, the difference between overall survival of responders and non-responders is particularly high in the TNBC subgroup, as shown in a comprehensive metaanalysis. 11 In this metaanalysis the pCR rate for TNBC was 33.6%, and the hazard ratio (HR) for improved overall survival of pCR patients vs. non-responders was 0.16 (95% CI 0.11-0.25) for the TNBC subgroup. Neoadjuvant approaches are therefore a central treatment strategy for TNBC. 4, 12 Standardized systems for measurement of neoadjuvant response and residual cancer burden have been published. 13, 14 In a metaanalysis of 3337 patients from 10 clinical studies, dose-dense therapy approaches were particularly effective in the HR-negative subgroup measured by immunohistochemistry. 15 However, this has not been observed in all clinical trials and it is also dependent on the selection and risk of the luminal tumors that are used for comparison as well as the method used for molecular classification.
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Modified chemotherapy concepts including platinum compounds -new biomarker strategies Neoadjuvant approaches: The addition of platinum has been investigated as a promising approach for optimization of chemotherapy. In the GeparSixto trial, increased pCR rates 17 and improved survival rates 18 with neoadjuvant carboplatin compared to a non-standard liposomal anthracycline and taxane control arm have been observed in the TNBC, but not in the HER2-pos subgroup. The increase in pCR caused by carboplatin was greater in a)
patients without a BRCA1/2 mutation 18 and b) patients with increased tumor-infiltrating lymphocytes. 19 The homologous recombination deficiency (HRD) assay that has the aim to measure so-called genomic scars as indicators of HRD showed that HRD-assay high scoring tumors had higher pCR rates compared to HR-non-deficient tumors, but this was observed independent of treatment and the effect of carboplatin could not be predicted. 20 In the CALGB 40603 trial, pCR rates in the overall TNBC trial population were improved with addition of neoadjuvant carboplatin (and bevacizumab), 21 but the increased pCR rate was not linked to an improved survival of the experimental treatment groups. 22 This is an example illustrating that pCR is an important prognostic parameter on a patient level, but not necessarily on a trial level. The Geicam 2006-03 trial has not shown any difference between pCR rates with neoadjuvant EC followed by docetaxel with or without carboplatin.
This trial was restricted to an immunohistochemically defined basal-like subtype of TNBC and suggested no advantage to addition of platinum as an alkylating agent when patients had already received an alkylating agent regimen. In this trial the baseline treatment was weaker in the carboplatin containing arm compared to the control arm. 24 No a priori specified biological sub-group analyses were conducted.
The phase 3 TNT trial has directly compared carboplatin vs. docetaxel in TNBC and patients with germline BRCA1/2 mutation and specified a priori biological subgroup analyses. In this trial, so far reported only as an abstract, the response to carboplatin therapy was not superior to that standard of care, docetaxel in the overall unselected TNBC group. The response to carboplatin was significantly greater than to docetaxel in patients with BRCA1/2 mutated tumors, was similar to docetaxel in PAM50 basal-like cancers and was significantly inferior to docetaxel in the non-basal-like subtype, although the numbers in this non-basallike group were very small. 25 The HRD-assay, 26 identified a high score group with higher response rates in both therapy arms; but the score appeared not to predict platinumspecific response. These data are supported by previous non-randomized data in a phase 2 trial of 20 patients with BRCA mutation and metastatic breast cancer that has reported an overall response rate of 80% with single-agent cisplatin therapy. 27 Similarly, in the nonrandomized neo-adjuvant PreCOG 0105 28 , and the non-randomized TBCRC009 trial 29 in the metastatic setting, increased responses to platinum therapy were observed in the group of patients with BRCA mutations. In these trials as well as an additional analysis, 30 response was also linked to higher HRD-assay scores. It should be noted that without a non-platinum control arm it is not possible to assess the specificity of the HRD-assay for platinum as opposed to standard of care therapy response, and additional investigations are required.
Post-neoadjuvant strategies:
In the post-neoadjuvant setting, the CREATE-X trial 31 has reported that postneoadjuvant capecitabine leads to improved survival in poor-responders to neoadjuvant therapy. The TNBC subgroup (37% of patients) showed a hazard ratio (HR) of 0.58 in favor of postneoadjuvant capecitabine treatment. The IBSCG 22-00 trial 32 has investigated a metronomic maintenance therapy with cyclophosphamide and methotrexate after adjuvant or neoadjuvant chemotherapy. In the subgroup of nodal-positive TNBC a nonsignificant trend for improved DFS was observed, which was not seen in the complete study cohort. Furthermore, there are no predictive markers that are significant across all different studies.
For example, BRCA1/2 mutations are predictive for increased response to cisplatinum or carboplatin therapy in the metastatic setting in the TNT and TBCRC009 trial. In contrast in the neoadjuvant GeparSixto trial, patients with BRCA1/2 mutations had a higher response rate to the control therapy (but a lower increase in response rate with the addition of platinum therapy). In this trial a high response of treatment naïve patients with BRCA1/2 mutations to control arm anthracycline/taxane based therapy appears to undermine any additional effect of platinum on response rates in a chemotherapy naïve primary treatment setting.
Biologic and genomic alterations as a basis for new therapeutic strategies

Definition of TNBC by current guidelines and subtypes identified by classical pathology
The histological presentation of classical TNBCs is characterized by high mutational rate, high nuclear grade as well as the presence of necrosis and inflammatory infiltrates. However, these characteristics are observed in other high-grade breast carcinomas, as well. Therefore, in clinical practice, TNBC is currently defined by what it is not. TNBCs have in common that they are negative for the standard breast cancer markers and cannot be treated by established therapies such as endocrine and anti-HER2 therapy. This designation is helpful in the clinical setting since it provides a convenient name for this group of tumors for clinical decisions. Nevertheless, we cannot understand the true biology of these tumors using this definition.
The updated guidelines on determination of hormone receptors and HER2 status in breast cancer have also influenced which tumors are designated triple-negative. The current guidelines 35 have changed the cutpoint for ER and PR from 10% to 1%. This was based on historical studies 36 that have shown a benefit from endocrine therapy even with very low levels of hormone receptors. Gene expression analysis has shown that 76% of tumors with very low (1-9%) hormone receptor expression were ESR1 negative on the mRNA level, 48%
were classified as basal-like and only 8% classified as luminal, all of them as luminal B. 37 It is an open question if these tumors would also benefit from new therapeutic strategies that are currently developed for TNBC. The lower cutpoints for ER and PR therefore are useful to increase the number of patients eligible for endocrine therapy, but they might decrease the number of patients eligible for future TNBC-specific therapies, depending on the inclusion criteria in current clinical TNBC trials.
Some subtypes of TNBC can be reliably identified upon histopathological evaluation of H&E slides, in particular tumors such as adenoid-cystic carcinomas (ADCC). These tumors are histologically similar to salivary gland tumors and show a typical MYB-NFIB gene fusion that is also found in salivary gland ADCCs. 38, 39 In contrast to classical TNBC, they have a low proliferation rate and a comparably good prognosis even with less aggressive treatment. 40, 41 Several other rare subtypes of TNBC have been described, including low grade adenosquamous carcinoma 42 , fibromatosis-like metaplastic carcinoma, 43 and secretory carcinoma 44 , and the published small cases-series suggest that these subtypes might also have an improved prognosis. Therefore, the identification of these subtypes is important for selection of less aggressive individual patient treatment strategies and these lowproliferating tumors should not be included in TNBC clinical trials.
Gene expression profiling strategies for classification of TNBC
There have been several successful approaches to classify TNBC by gene expression profiling
showing that basal markers, including keratin 5, EGFR and laminin, are typical for TNBC. 45, 46 Basal-like tumors are enriched in TNBCs, but 21% of TNBC are not basal-like, and 31% of basal-like tumors are not triple-negative. 47 In a gene expression study specifically focused on TNBC, additional subtypes have been identified, 48 including two basal-like (BL1 and BL2), an immunomodulatory (IM), a mesenchymal (M), a mesenchymal stem-like (MSL), and a luminal androgen receptor (LAR)
type. Interestingly, important markers relevant for these additional subtypes derive from stromal cells, in particular fibroblasts and T-cells, which provides an additional molecular validation of the histopathological observation of increased tumor-infiltrating lymphocytes in TNBC. 47 Recently, these subtypes have been revised and limited to four distinct subtypes, i.e. BL1 and BL2, M, and LAR type TNBC. 49 In a similar approach, Burstein et al. 50 based on the measurement of a total of 2188 genes, but recently it has been suggested that the number of genes could be reduced to 101 genes, 54 which might be more manageable in the daily diagnostic practice. Currently, these molecular subtypes are not part of routine assessment of TNBC, but they provide a framework for the design of clinical studies that focus on the most relevant molecular alterations in the diverse TNBC subgroups.
Tumor-infiltrating lymphocytes (TILs) as indicators of immunogenicity
The tumor-associated immunological infiltrate is an important classical pathology parameter for TNBC. Traditionally, the subtype of medullary breast cancer shows a dominant lymphocytic infiltrate and a comparably good prognosis. 55, 56 The most important parameter for the clinical behavior of this tumor type is the lymphocytic infiltrate, and conventional invasive-ductal carcinomas with an increased lymphocytic infiltrate have a similarly good prognosis as the medullary group. 57 Consequently, the current WHO classification has suggested that these tumors are not separate entities but represent the end of a spectrum of tumors that are characterized by an immunologically active tumor microenvironment. 58 Some candidate mechanisms for how an activated immunological microenvironment may be maintained by the tumor in subpopulations of TNBC have been proposed. 59 This is in line with a large number of studies investigating TILs in breast cancer. 60 These studies have shown that TILs are linked to increased response to neoadjuvant chemotherapy in breast cancer. 33 Neoadjuvant response is a well-established prognostic factor in triplenegative breast cancer, 4, 11 and increased TIL levels have also been shown to be linked to improved prognosis in this subtype. 34 ,61 The focus on immune parameters is quite important for upcoming immunotherapy approaches including immune-checkpoint inhibitors, and the current data suggest that the modulation of the immune response might be able to increase therapy response in subgroups of TNBC. 62 Interestingly, the immunosuppressive parameters PD1 and PD-L1 show a positive correlation with the other immunological markers as well as with tumorinfiltrating lymphocytes.
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BRCA1/2 mutation status and homologous recombination deficiency (HRD)
The majority of hereditary (i.e. BRCA1/2 mutated) breast cancers show a triple negative profile. 64 However, since BRCA-associated breast cancers are significantly less common compared to cases of TNBC, the majority of unselected TNBC are still wildtype for BRCA1/2.
Tumors with BRCA1 or 2 mutations typically have a deficiency in homologous recombination (HRD) which means that damage to the DNA structure, in particular DNA double-strand breaks, and stalled or collapsed DNA replication forks, cannot be repaired properly. Over the life of the tumor, HDR leads to typical alterations in the DNA structure, which have been termed "genomic scars". Typical characteristics of BRCA1/2 mutation associated genomic scars are large regions of loss-of-heterozygosity (LOH), increased numbers of telomeric allelic imbalances (NtAI) and large scale transitions (LST). 65 Recently, typical rearrangement signatures with high numbers of tandem duplications have been linked to basal-like TNBC with high HRD index and BRCA mutations. 70 Interestingly, these alterations are typical for BRCA-mutant tumors but they have also been identified in tumors without a BRCA mutation.
The currently described genomic scars have high sensitivity for BRCA1 or 2 mutation but appear to have poor specificity and positive predictive value for identifying tumor response that is specific to platinums rather than standard of care chemotherapy. Taken together this suggests that some BRCA wild-type tumors have a deficiency in homologous combination 66 but that biomarkers that have clinical utility must still be sought.
At present, even in the absence of a BRCA mutation a significant proportion of TNBCs show biologic similarities with BRCA-associated breast cancers. This phenomenon is commonly referred to as BRCAness. 67 It is a current major research focus to define molecular markers of HDR that can be used to select patients whose tumors will develop specific responses to PARP inhibitor or platinum therapy. 68 Similar to the immunological parameters, BRCA mutations and genomic scars are relevant molecular alterations for development and progression of TNBC, rather than specific markers for a defined subtype.
Genomic analysis of somatic mutations and copy number changes in triple-negative tumors
Comprehensive genomic investigations 69, 70 have provided extensive data on the mutational landscape of breast cancer, but they have not identified any tumor mutations that are characteristic for TNBC. The total number of non-synonymous somatic mutations measured by whole-exome sequencing in the TCGA database is higher in TNBC (median 49 mutations) compared to Luminal BC (median 27 mutations). 71 Nevertheless, this mutational load in TNBC is still relatively low compared to malignant melanoma, NSCLC or MSI-colon cancer.
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The main breast cancer mutations in PIK3CA and p53 are also the predominant mutations in TNBC, which higher mutations rated for p53 (50-80%) and slightly lower rates for PIK3CA
(10-20%) compared to luminal tumors. 73, 70 PIK3CA mutations have been found to be increased in androgen-receptor positive TNBC. 74 It has been shown that copy number alterations (CNAs) and mutations are predominant in different subsets of tumors, 75 and breast cancer, including TNBC, is a typical example of the C-class of tumors that show predominantly copy number alterations, 76 but also a high rate of tp53 mutations. 75 Fusion genes including genes encoding microtubule-associated serinethreonine kinase (MAST) and members of the Notch family have been described in subsets of breast cancer. 77 Different types of Notch gene rearrangement, which might be targetable by agents such as gamma-secretase inhibitors, are found in subsets of TNBC.
New targeted therapeutic approaches in TNBC Immune checkpoint inhibitors
There are several reasons why TNBC is regarded the optimal subtype of all breast cancers for immune checkpoint inhibition, with monoclonal antibodies including pembrolizumab weeks. Most importantly, the noted median duration of response was not yet reached, and a subset of patients also showed long-lasting responses. In the NCT01375842 phase 1a multicenter trial, 27 patients with pretreated metastatic PD-L1 positive TNBC were treated with PD-L1 inhibitor atezolizumab (MPDL3280A), leading to an ORR of 24%. 79 It is known that conventional chemotherapy can be immunogenic, 80 which suggests a synergy between chemotherapy and immune therapy. In a phase 1b expansion trial 81 patients with metastatic TNBC with ≤ 3 prior lines of therapy were treated with atezolizumab in combination with nab-paclitaxel, followed by maintenance therapy with atezolizumab until loss of clinical benefit. Primary endpoints were safety and tolerability; secondary endpoints included clinical activity. A PD-L1 expression in at least ≥5% of TILs was a prerequisite for participation in the trial. 32 patients were evaluable for safety analysis at a median follow-up of 5.21 months. The most common treatment-related adverse-event was a decrease in neutrophil counts (occurring at grade 3-4 in 41% of cases). Overall response rates were 67%, 25%, and 29% for patients in first, second and third line, respectively.
A corresponding phase trial III is currently recruiting patients world-wide. This trial (IMpassion130, NCT02425891) is a phase III, multicenter, randomized placebo-controlled study of atezolizumab in combination with nab-paclitaxel compared with placebo with nabpaclitaxel for patients with first-line metastatic TNBC. In this trial, PD-L1 positivity is not required, since it is increasingly recognized that PD-L1 positivity might not predict an increased chance of response against PD-L1 inhibitors.
These promising results have fostered initiation of a plethora of clinical trials including alternative PD1/PD-L1 inhibitors as well as combination regimens with tyrosine kinase inhibitors, MEK inhibitors, PI3K inhibitors, anti-angiogenic agents or combination with other checkpoint inhibitors 82 or co-stimulatory molecules. Table 3 lists selected clinical trials of PD1 or PD-L1 inhibition that are currently recruiting patients.
PARP-inhibitors and other genetics-based therapy strategies
Preclinical and clinical studies show that BRCA-mutated tumors have increased responses to PARP-inhibitor therapy, which can be elegantly explained by the concept of synthetic lethality. 83 This concept implies that simultaneous loss of function of two genes, such as those caused by BRCA-mutation and PARP-inhibition, results in cell death, while loss of only one does not change cellular viability. One mechanistic model for synthetic lethality suggests that PARP inhibitors induce single-strand DNA breaks or trap PARP-1 on DNA causing DNA replication forks to arrest and progress to double-strand breaks. BRCA-deficient tumors are not able to repair these double-strand breaks and are therefore more sensitive to the PARP inhibitor. It should be noted that additional alternative mechanistic explanations have been suggested (for details see 84 ).
In the NCT00494234 non-randomized phase 2 trial patients with BRCA-mutated advanced breast cancer including those with TNBC were treated with olaparib 100mg or 400 mg twice daily (table 2) . In particular in the group treated with 400mg, an objective response rate of 41% was observed. 85 In the neoadjuvant I-SPY2 trial 86 , an adaptive trial design was used to evaluate the combination of the PARP inhibitor veliparib with carboplatin in addition to a standard anthracycline taxane neoadjuvant therapy. The addition of veliparib-carboplatin increased pCR rate in the TNBC group from 26% to 51%. Due to the trial design it is not possible to attribute the increase in response to the PARP inhibitor or the platinum or a synergy in the combination.
Based on this phase 2 results, the Brightness phase 3 87 
Bevacizumab
Bevacizumab has been shown to increase pCR rates in triple-negative breast cancer in the GeparQuinto trial 99, 100 (Bev: 36% vs. control: 21%; ypT0ypN0), the CALGB 40603 trial 21, 22 (59% vs. 48%; pT0/is), the SWOG S0800 101 trial (59% vs. 29%; ypT0/isyN0) and the ARTemis trial 102 (45% vs. 31%, ypT0/isyN0). In contrast, in the NSABP-B40 trial, the increased pCR rate with bevacizumab was observed only in the hormone receptor positive subgroup (23% vs. 15%), 103 but not in the TN-subgroup (52% vs. 47%). Up to now, most neoadjuvant trials have not reported a survival advantage of the bevacizumab treatment. The exception is NSABP-B40, where a significant overall but not disease-free survival benefit that was observed. 104 In the adjuvant BEATRICE study, no difference in invasive-disease free survival and in overall survival was reported with the addition of bevacizumab to adjuvant chemotherapy. 105 It has been suggested that the current data does not allow the use of bevacizumab in early breast cancer, but that the combined evaluation of the neoadjuvant trials as well as biomarker-based stratifications might allow a better understanding of the clinical benefit of bevacizumab in defined subgroups.
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Androgen receptor inhibitors
There is a large and increasing body of evidence suggesting a potential role for androgen receptor (AR) targeting in a subset of breast cancer patients. In a recent meta-analysis of thirteen relevant studies including 2826 patients with TNBC an AR positivity rate of 24.4% was observed. 52 
